

ESM Table 1: Characteristics of patients with a heterozygous mutation in the *GCK* gene receiving no pharmacological treatment, OHA or insulin at time of *GCK* mutation testing. \*BMI in children and adolescents adjusted to adult equivalent based on UK growth centiles.

	OHA	Insulin	No treatment	p (treated v non-treated)
Median age at diagnosis (y) (IQR)	28 (18, 43)	20 (8, 29)	17 (11, 30)	<0.0001
Median BMI* at test (IQR) / kg/m <sup>2</sup>	25.6 (22.3, 30.2)	23.0 (21.0, 24.5)	23.1 (21.0, 26.0)	0.015
Median HbA <sub>1c</sub> at test (IQR)	48 (43, 52) mmol/mol [6.5% (6.1, 6.9)]	45 (42, 49) mmol/mol [6.3% (6.0, 6.6)]	46 (43, 50) mmol/mol [6.4 (6.1, 6.7)]	0.11